HCP behaviour change is measured by comparing a clinician’s knowledge, confidence and intended practice before and after an education programme, then confirming real-world change at a follow-up weeks later, the gap between the two is the “distance travelled.” On Moore’s hierarchy of educational outcomes this is Level 5 (performance change), the level pharma increasingly asks for at renewal. Yoke Health (Yoke Enterprises Ltd) measures it automatically, capturing confidence shifts, decision accuracy and six-week behaviour follow-ups across every HCP interaction and rolling them into a single automated proof report.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“headline”: “Behaviour Change Measurement in Medical Education: A Definitive Guide”,
“author”: {
“@type”: “Person”,
“name”: “Matt Davies”,
“url”: “https://www.linkedin.com/in/mattdavies75”
},
“publisher”: {
“@type”: “Organization”,
“name”: “Yoke Health”,
“url”: “https://yokehealth.com”
},
“datePublished”: “2026-04-14”,
“description”: “A comprehensive guide to measuring behaviour change in HCP education using Mooreu2019s Level 5 and distance travelled methodology.”,
“keywords”: [
“behaviour change measurement”,
“medical education”,
“distance travelled”,
“Mooreu2019s Level 5”,
“HCP education”,
“MedComms”
],
“about”: {
“@type”: “Thing”,
“name”: “Behaviour Change Measurement in Medical Education”
}
}

{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “How is behaviour change measurement different from competency assessment?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Competency assessment measures whether an HCP can perform a task correctly (knowledge and skill). Behaviour change measurement measures whether they do perform it differently in practice after education. An HCP can pass a competency test without changing their clinical behaviour.”
}
},
{
“@type”: “Question”,
“name”: “What is Mooreu2019s Level 5 measurement?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Mooreu2019s Level 5 refers to the Performance level of Mooreu2019s Continuum of Educational Outcomes u2014 the point at which an HCP demonstrates changed clinical practice as a result of education. It requires pre-education baseline data, post-education measurement, and follow-up evidence that the change has been sustained. It is the standard used by pharma medical affairs teams to evaluate education ROI.”
}
},
{
“@type”: “Question”,
“name”: “What is distance travelled measurement in HCP education?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Distance travelled is a measurement methodology that quantifies how far a healthcare professional has moved from their starting point in terms of knowledge, confidence, and clinical practice after completing an educational programme. A distance travelled score of 38 percentage points means an HCP moved 38% closer to the target clinical behaviour u2014 evidence that can be presented to pharma medical affairs teams as proof of education ROI.”
}
},
{
“@type”: “Question”,
“name”: “What do pharma companies use behaviour change data for?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Pharma medical affairs teams use behaviour change data for: demonstrating education programme ROI, supporting regulatory filings that require evidence of HCP education impact, MedComms agency selection and tender evaluation, programme renewal justification, and medical affairs annual reporting.”
}
},
{
“@type”: “Question”,
“name”: “Can behaviour change measurement be done retrospectively?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No. Behaviour change measurement requires a pre-education baseline captured before the programme begins. If baseline data was not captured, it is not possible to calculate distance travelled retroactively. This is why building measurement infrastructure before deploying educational content is critical.”
}
}
]
}

Behaviour Change Measurement in Medical Education

Behaviour change measurement in healthcare education is the practice of quantifying whether a medical education programme has changed how a healthcare professional (HCP) thinks, acts, or prescribes, not simply whether they attended or completed it.

In regulated healthcare environments, pharma companies, biotech firms, and MedComms agencies are increasingly required to demonstrate that their investment in HCP education has produced a measurable outcome. Completion rates and attendance figures are insufficient. Behaviour change measurement answers the question that medical affairs teams actually need to answer: did this education change clinical practice?

Why Completion Rates Are Not Enough

For more than a decade, the medical education industry relied on two primary metrics: attendance rates and completion rates. These metrics measure exposure. They do not measure impact.

A healthcare professional can sit through a 60-minute medical education programme and retain nothing that changes their clinical practice. A high completion rate only tells you that people pressed the finish button. It tells you nothing about whether a single one of them will prescribe differently tomorrow.

The shift in pharma and MedComms is from attendance evidence to behaviour evidence.

The Behaviour Change Measurement Framework

The most widely used framework for measuring behaviour change in medical education is Moore’s Continuum of Outcomes (Moore, Green & Gallis, 2009), which defines 7 levels of educational impact. Level 5, Performance, is the gold standard. It requires:

  1. A pre-education baseline assessment (before the programme)
  2. A post-education assessment (immediately after)
  3. A 6-week follow-up survey (confirming behaviour is sustained in practice)

The difference between baseline and follow-up scores is the distance travelled.

Distance Travelled: Quantifying the Behaviour Change Gap

Distance travelled is Yoke Health’s term for the measurable gap between where an HCP started and where they arrived after completing a medical education programme. A distance travelled score of 38 percentage points at 6-week follow-up means the programme durably moved HCPs 38% closer to the target clinical behaviour, evidence that can be presented directly to pharma medical affairs and regulatory teams.

What Behaviour Change Measurement Requires from Your Platform

To generate credible behaviour change data, a medical education platform needs:

  • Pre-assessment capture: knowledge, confidence, and practice intent questions before the programme
  • Interaction tracking, not just completion tracking, but which questions, how long, what responses
  • Automated 6-week follow-up: survey delivery, cohort-level reporting, comparison vs baseline
  • Distance travelled calculation: proof report generation for pharma clients, GDPR-compliant anonymisation

Behaviour Change Measurement in MedComms: The Proof Gap

MedComms agencies face a specific challenge: pharma clients increasingly ask for proof that education has worked, but most agency delivery infrastructure was not built to capture behaviour change data. Agencies that can deliver behaviour change proof reports hold a significant competitive advantage in pharma tender processes and programme renewals.

How Yoke Health Automates Behaviour Change Measurement

Yoke Health’s platform (iHive, iCases, iLearning) was built with behaviour change measurement as its core function, not an add-on. All three platforms feed into a unified dashboard showing distance travelled scores at cohort and individual level, with GDPR-compliant anonymisation for pharma client reporting.

→ iHive Platform: Perpetual HCP Engagement
→ MedComms Agency Partnership
→ Biotech Pre-launch HCP Education
→ iLearning: CME with Automated Measurement

Frequently Asked Questions

How is behaviour change measurement different from competency assessment?

Competency assessment measures whether an HCP can perform a task correctly. Behaviour change measurement measures whether they do perform it differently in practice after education. An HCP can pass a competency test without changing their clinical behaviour.

What is Moore’s Level 5 measurement?

Moore’s Level 5 refers to the “Performance” level of Moore’s Continuum of Educational Outcomes, the point at which an HCP demonstrates changed clinical practice as a result of education. It requires pre-education baseline data, post-education measurement, and follow-up evidence that the change has been sustained. It is the standard used by pharma medical affairs teams to evaluate education ROI.

What do pharma companies use behaviour change data for?

Pharma medical affairs teams use behaviour change data for: demonstrating education programme ROI, supporting regulatory filings, MedComms agency selection and tender evaluation, programme renewal justification, and medical affairs annual reporting.

Can behaviour change measurement be done retrospectively?

No. Behaviour change measurement requires a pre-education baseline captured before the programme begins. If baseline data was not captured, it is not possible to calculate distance travelled retroactively. This is why building measurement infrastructure before deploying educational content is critical.

Maintained by the Yoke Health team. Last updated: April 2026.

{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“@id”: “https://yokehealth.com/behaviour-change-measurement/#faq”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “What is HCP behaviour change measurement?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Measuring whether a healthcare professional altered clinical practice as a result of an education intervention, and whether that altered practice changed patient outcomes. Operationalised via Moore’s 7-level framework, Levels 4 (clinical practice change) and 5 (patient outcome change) are the ones that matter to pharma medical affairs. Most medical education programmes still report only Levels 1-2.”
}
},
{
“@type”: “Question”,
“name”: “What’s the difference between Moore’s Levels 1, 2, 3, 4, and 5?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “L1 participation (HCP attended). L2 satisfaction (HCP rated it positively). L3 learning (HCP knowledge changed on post-test). L4 competence + performance (HCP intends to change practice and demonstrably did). L5 patient health (patient outcomes shifted measurably). The further down the framework you can prove, the more your education spend defends itself in the next RFP cycle.”
}
},
{
“@type”: “Question”,
“name”: “How does Yoke capture behaviour change data automatically?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Structured signals at the point of HCP engagement: which content was viewed, which decision-support tools were used, which follow-up actions were taken in the practice flow. Signals are scored on a composite 100-point scale and written to the per-tenant proof dashboard in real time. No manual survey-chasing. 11 MedComms agencies currently route their proof data through this engine.”
}
},
{
“@type”: “Question”,
“name”: “What can pharma clients actually do with the proof report?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Three things. (1) Defend the spend internally to medical affairs leadership at quarterly review. (2) Justify renewals by showing measurable change vs the prior quarter. (3) Present at congress and to KOL networks as evidence the education programme worked. Yoke proof reports are exportable as PDF with full data lineage, or shareable as read-only links for cross-team access.”
}
},
{
“@type”: “Question”,
“name”: “How is HCP retention measured at 6 weeks?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Six weeks is the standard interval at which an HCP’s behaviour change either persists or reverts. Yoke runs an automated re-engagement check at week 6: does the HCP’s clinical practice still reflect the intervention? Median retention across 38 pharma brand programmes (2025): 47%. Programmes that build a 6-week reinforcement touchpoint see retention rise to 71%. Yoke recommends and provisions both touchpoints by default.”
}
},
{
“@type”: “Question”,
“name”: “Why do most medical education programmes fail to measure behaviour change?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Three reasons. (1) The measurement infrastructure costs more than the programme budget if built from scratch. (2) Most agencies don’t have an in-house technical team to run it. (3) The agency-pharma contract often doesn’t require Level 4-5 reporting, so it’s never built. Yoke removes barriers 1 and 2; pharma RFPs increasingly remove barrier 3 by making Level 4-5 reporting a contractual requirement.”
}
},
{
“@type”: “Question”,
“name”: “What stats should a MedComms agency be able to quote on demand?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Five: (1) cost per HCP engaged, (2) cost per documented behaviour change event, (3) Level 4 outcome rate, (4) Level 5 outcome rate, (5) 6-week retention rate. If your agency cannot answer all five within 60 seconds for any active brand, your medical affairs client will eventually notice. Yoke surfaces all five on the default proof dashboard.”
}
},
{
“@type”: “Question”,
“name”: “How long does it take to set up behaviour change measurement on a new programme?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Under 60 minutes for the platform itself (self-serve activation via Stripe → Terraform). Calibrating the Q/A and behavioural signal definitions for a specific therapy area: 1-2 working days with the agency’s medical lead. First meaningful behavioural data: 3-4 weeks after launch. First Level 5 outcomes: 6 weeks. 11 MedComms agencies completed this calibration in 2025; median time-to-first-signal was 22 days.”
}
}
]
}